News | Ventricular Assist Devices (VAD) | June 09, 2015

UH Case Medical Center First in Ohio to Implant Impella RP Ventricular Assist Device

Hospital also participated in training through Abiomed Mobile Learning Lab

UH Case Medical Center, Impella RP, first in Ohio, Abiomed, Mobile Learning Lab

June 9, 2015 - University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in Ohio to implant a new device to treat right ventricular heart disease.

The Impella RP, made by Abiomed, addresses an unmet need of treating right heart failure in the setting of right ventricular (RV) infarction or after complex heart surgery, including heart transplant. The device allows the right side of the heart to recover without the upfront need for invasive surgical intervention.

University Hospitals' multidisciplinary team - including interventional cardiologist M. Najeeb Osman, M.D., chief, Cardiac Rehabilitation and Intensive Care Unit and assistant clinical professor of medicine at Case Western Reserve University School of Medicine, and cardiac surgeon Benjamin Medalion, M.D., clinical associate professor of surgery at the School of Medicine - led a collaborative heart team in the catheterization lab during the first implantation at UH.

"The device sits inside the heart and takes blood from the right atrium and pushes it through the right side of the heart to the pulmonary artery, assisting the ailing right ventricle in its pumping function," said Sahil Parikh, M.D., director of the UH Harrington Heart & Vascular Institute Center for Research and Innovation and assistant professor of medicine at the School of Medicine. "This is an incredible breakthrough in treatment. It allows us to provide patients who were once untreatable with a new non- surgical option that serves as a bridge to transplant and/or recovery."

Traditional treatments for right ventricular issues are extremely limited. Many patients who experience RV dysfunction have exhausted interventional options and require invasive surgery but are at high risk for complications.

Right ventricular dysfunction has largely been underappreciated or undertreated despite its importance in such severe conditions as cardiogenic shock, largely due to the inability to support these patients without complex and highly invasive therapies. Cardiogenic shock limits the heart from pumping enough blood to vital organs such as the brain, lungs, liver and kidneys. Patients with severe RV dysfunction are at high risk for death, and open heart surgery and drug therapies have had limited success.

The Impella RP device allows for minimally invasive implantation done in the catheterization lab (about an hour procedure) and is effectively serving as a successful bridge to transplant and/or recovery and may get the patient through an acute phase of the illness.

"This is an invaluable and potentially lifesaving tool for patients with advanced heart failure with acute right heart failure," Osman said. "This new device will help us stabilize patients and buy precious time that enables them to be potential transplant candidates."

UH now offers the full spectrum of Impella pumps.

UH also participated in the Abiomed Mobile Learning Lab (MLL) program on June 5. The Abiomed Mobile Learning Lab is a highly interactive, facilitated learning experience that is brought directly to the hospital to train the hospital staff on the Impella heart pump.

The flagship Impella device, the Impella 2.5, recently received U.S. Food and Drug Administration (FDA) approval to treat high-risk percutaneous coronary intervention (PCI) patients. The procedure, Protected PCI, is offered at UH.

The Mobile Learning Lab offers cardiologists, nurses and cath lab staff at UH Case Medical Center a convenient opportunity to learn about the new technologies. The Mobile Learning Lab contains various Impella simulators, animations and key information, which are all presented by a team of Abiomed trainers.

For more information: www.uhhospitals.org

Related Content

Videos | Heart Failure

The University of Maryland Medical Center (UMMC) announced the first successful transplant of a genetically modified pig ...

Home January 11, 2022
Home
Feature | Heart Failure | By Dave Fornell, DAIC Editor

January 10, 2022 — The University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center ...

Home January 10, 2022
Home
News | Heart Failure

December 16, 2021 — MVP Health Care and The University of Vermont Health Network recently announced their joint Medicare ...

Home December 16, 2021
Home
News | Heart Failure

November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...

Home November 19, 2021
Home
News | Heart Failure

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

Home November 17, 2021
Home
News | Heart Failure

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

Home November 10, 2021
Home
News | Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

Home November 02, 2021
Home
News | Heart Failure

October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling ...

Home October 27, 2021
Home
News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
Subscribe Now